AzTrials
AzTrials

OCD3TOCNCT05843604

Cerebral and Cognitive Markers of Treatment Resistance in Obsessive Compulsive Disorder

An observational study of OCD, run by Centre Hospitalier Henri Laborit at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to define individual profiles of treatment resistants in order to find indicators and predictors of the therapeutic response. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
OCD
What is being tested?
Functional MRI
How many people
100 participants
Where
1 siteFrance
Study dates
3 Jul 2023to Sep 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients will be recruited from the Clinical Research Unit of Poitiers. All volunteer patients included in this study will be included regardless of the degree of resistance to treatment or the severity of their disease. Patients will not be hospitalized for the duration of the study unless their condition requires it. Healthy volunteers will be recruited locally by advertisement or through acquaintances, and will be matched to each patient based on age, gender, laterality, and education level. They must not have an acute pathology being treated, nor take psychotropic drugs, nor be followed in psychotherapy. In their history, we must not find hospitalization in a psychiatric environment or a psychiatric illness according to the M.I.N.I. version 5.0.0.

Who may be able to join

  • Obsessive compulsive disorder diagnosed according to Diagnostic and Statistical Manual 5 criteria (patients will be included regardless of the severity and resistance of their pathology and their levels of executive functions)
  • Understand and accept the constraints of the study
  • Be a beneficiary or affiliated to a Health Insurance scheme

Who cannot join

  • Present one of the diagnoses according to the criteria of the DSM 5: schizophrenic disorders, substance abuse or dependence to a substance according to the criteria of the M.I.N.I. version 5.0 (Sheehan et al., 1998)
  • Generalized anxiety disorder, social anxiety, nicotine dependence and history of a major depressive episode are not exclusion criteria according to the M.I.N.I. version 5.0 (Sheehan et al., 1998)
  • Have a serious intercurrent pathology
  • Being a pregnant woman
  • Being a woman of childbearing age without effective contraception.
  • Being hospitalized under duress or on an outpatient basis in a care program
  • Being under judicial protection (reinforced curatorship, guardianship)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Centre Hospitalier Henri Laborit

    Poitiers

    Damien Doolub, MD

    Recruiting

Other trials in France

About this study

Official title: Cerebral and Cognitive Markers of Treatment Resistance in Obsessive-compulsive Disorder: Towards Personalization of Patient Care

This study aims to define individual profiles of treatment resistants in order to find indicators and predictors of the therapeutic response.

Conditions
OCD
Being tested
Functional MRI
Keywords
functional MRI

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Functional MRIOther

    Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task

Study groups in NCT05843604
Study groupRoleWhat they receive
obsessive compulsive disorder patientsNot described
Receives: Other: Functional MRI
Control PatientsNot described
Receives: Other: Functional MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cerebral activity modification during N-back task

    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls

    Measured: Day 1

  2. Cerebral activity modification during Stroop task

    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls

    Measured: Day 1

  3. Cerebral activity modification during switching task (Monsell et Mizon task )

    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2023
  2. Study start3 Jul 2023
  3. Primary completionJul 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05843604
Sponsor's protocol ID
2022-A00463-40
Acronym
3TOC
Status last verified
Jan 2026
First submitted
25 Apr 2023
Last updated
13 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of OCD, run by Centre Hospitalier Henri Laborit at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Damien Doolub, MD (+33 (0)5 16 61 18, damien.doolub@ch-poitiers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cerebral activity modification during N-back task (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in